Publicacións en colaboración con investigadores/as de Centro Medico Teknon (52)

2025

  1. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

    American Journal of Hematology, Vol. 100, Núm. 2, pp. 272-284

2024

  1. Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)

    Cancers, Vol. 16, Núm. 9

  2. Nutritional and Morphofunctional Assessment of Post-ICU Patients with COVID-19 at Hospital Discharge: NutriEcoMuscle Study

    Nutrients, Vol. 16, Núm. 6

  3. Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 906-923

  4. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946

  5. Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis

    BJS Open, Vol. 8, Núm. 1

2023

  1. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594

  2. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study

    Drugs, Vol. 83, Núm. 12, pp. 1111-1123

  3. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

  4. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS: A Case Series and Review of the Literature

    Retina (Philadelphia, Pa.), Vol. 42, Núm. 3, pp. 465-475

  2. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  3. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS

    Dermatology, Vol. 238, Núm. 2, pp. 320-328

  4. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  5. Incomplete Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery)

    Journal of the European Academy of Dermatology and Venereology

  6. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  7. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer –Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 5, pp. 451-458

2021

  1. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

    Vaccine, Vol. 39, Núm. 11, pp. 1598-1608

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  3. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48